Decitabine combined with minimally myelosuppressive therapy for induction of remission in pediatric high-risk acute myeloid leukemia with chromosome 5q deletion: a report of three cases

• DOI: 10.1007/s12185-022-03309-9
• Publication Date: 2022-02-19T02:06:42Z
• Authors: Shengqin Cheng; Peifang Xiao; Juxiang Wang; Zhiheng Li; Li Gao; Jiajia Zheng; Yixin Hu; Xin Ding; Jing Ling; Qin Lu; Jian Pan; Bohan Li; Jun Lu; Yi Wang; Raul C. Ribeiro; Shaoyan Hu
• Keywords: Chromosome Aberrations; 0303 health sciences; Adolescent; Remission Induction; Cytarabine; Hematopoietic Stem Cell Transplantation; Abnormal Karyotype; Decitabine; 3. Good health; Leukemia, Myeloid, Acute; 03 medical and health sciences; Antineoplastic Combined Chemotherapy Protocols; Humans; Chromosome Deletion; Child

Cases of pediatric acute myeloid leukemia (AML) with complex karyotypes including chromosome 5 abnormalities are rare and have a very poor prognosis. Management of AML with monosomy 5/del(5q) has been inconsistent. We treated three adolescents with this AML subtype using combined low-dose cytarabine and mitoxantrone, concurrently with decitabine and G-CSF, for remission induction. Decitabine was also included in the conditioning regimen before hematopoietic cell transplantation (HCT). All three patients achieved complete remission after treatment with this combination therapy. The treatment was well tolerated, and the patients are alive and free of disease at 3.6, 3.2, and 3.0 years after HCT, respectively.